ImmunityBio (IBRX) Net Cash Flow (2014 - 2026)

ImmunityBio (IBRX) has reported Net Cash Flow for 13 consecutive years, with $116.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 241.23% year-over-year to $116.9 million; the TTM figure through Mar 2026 stood at $145.2 million (up 300.99% YoY), while the FY2025 annual figure was -$54.5 million, up 55.31% from the prior year.
• Net Cash Flow improved to $116.9 million in Q1 2026 per IBRX's latest filing, from $28.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $134.5 million in Q3 2023 and bottomed at -$144.5 million in Q1 2022.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of $319000.0 in 2022.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1564.0% — and 2023, when it surged 27334.8%.
• ImmunityBio's Net Cash Flow stood at $319000.0 in 2022, then soared by 27334.8% to $87.5 million in 2023, then tumbled by 63.87% to $31.6 million in 2024, then dropped by 11.05% to $28.1 million in 2025, then jumped by 315.56% to $116.9 million in 2026.
• Business Quant data shows IBRX's Net Cash Flow at $116.9 million in Q1 2026, $28.1 million in Q4 2025, and -$76.7 million in Q3 2025.